Longeveron Inc(LGVN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LGVN Longeveron Inc

交易中 05-21 10:41:45 EDT

0.7100

+0.0035

+0.50%

最高0.7256	最低0.7000	成交量11.10万
今开0.7200	昨收0.7065	日振幅3.62%
总市值2,211万	流通市值1,903万	总股本3,115万
成交额7.88万	换手率0.41%	流通股本2,680万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":0.71,"timestamp":1779374040014,"preClose":0.7065,"halted":0,"volume":110984,"delay":0,"changeRate":0.0049539985845717584,"floatShares":26803700,"shares":31146337,"eps":-1.119466,"marketStatus":"交易中","change":0.0035,"latestTime":"05-21 10:41:45 EDT","open":0.72,"high":0.7256,"low":0.7,"amount":78823.7112856,"amplitude":0.036235,"askPrice":0.7257,"askSize":32,"bidPrice":0.71,"bidSize":432,"shortable":3,"etf":0,"ttmEps":-1.119466,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779393600000},"marketStatusCode":2,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":0.7065,"preHourTrading":{"tag":"盘前","latestPrice":0.7257,"preClose":0.7065,"latestTime":"09:05 EDT","volume":615,"amount":435.3665196,"timestamp":1779368704038,"change":0.0192,"changeRate":0.027176,"amplitude":0.027176},"postHourTrading":{"tag":"盘后","latestPrice":0.7488,"preClose":0.7065,"latestTime":"19:54 EDT","volume":7967,"amount":6072.1149,"timestamp":1779321297335,"change":0.0423,"changeRate":0.059873,"amplitude":0.104034},"volumeRatio":0.985695},"requestUrl":"/m/hq/s/LGVN","defaultTab":"news","newsList":[{"id":"1148764017","title":"Longeveron致股东信：阐述公司战略、合作路径及2026年核心任务","url":"https://stock-news.laohu8.com/highlight/detail?id=1148764017","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148764017?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:07","pubTimestamp":1779307636,"startTime":"0","endTime":"0","summary":"Longeveron Inc向股东发布公开信，详细阐述了公司的核心战略框架、战略合作模式以及为2026年设定的关键发展目标。信件重点说明了公司推进业务增长与创造长期价值的规划路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158339007","title":"Longeveron宣布独立数据监察委员会正面审阅并建议完成针对左心发育不全综合征的2B期干细胞疗法临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1158339007","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158339007?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:10","pubTimestamp":1778505015,"startTime":"0","endTime":"0","summary":"Longeveron Inc宣布，其独立数据监察委员会已完成对一项针对左心发育不全综合征（HLHS）的2B期干细胞疗法临床试验的中期数据审阅。委员会审阅后给出了正面意见，并建议公司按计划完成该项临床试验。\n此项临床试验旨在评估Longeveron的干细胞疗法对HLHS患儿的治疗效果与安全性。独立数据监察委员会的审阅结论为试验的继续进行提供了支持，标志着该疗法在关键开发阶段取得了积极进展。公司表示将遵循委员会的建议，持续推进试验直至完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178616204","title":"Longeveron与美国FDA召开建设性C类会议，为Elpis II期2B临床试验数据揭晓铺路，该试验评估左心发育不全综合征疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1178616204","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178616204?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:07","pubTimestamp":1778270843,"startTime":"0","endTime":"0","summary":"在备受期待的Elpis II期2B临床试验数据揭晓之前，Longeveron Inc宣布与美国食品药品监督管理局（FDA）成功举行了一次建设性的C类会议。此次会议的核心议题，是评估针对左心发育不全综合征（HLHS）的潜在疗法。\n这次及时的沟通，为公司未来与监管机构的互动奠定了积极基调。会议聚焦于即将到来的临床试验数据，为后续可能的监管提交路径进行了初步探讨。对于关注HLHS这一复杂先天性心脏病治疗进展的投资者和医学界而言，此举标志着研发进程中的一个重要节点。\n随着数据读出的临近，此次与FDA的建设性对话，有望为Longeveron在该关键领域的后续开发策略提供清晰指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618918518","title":"美国OTC市场Lianbio盘中异动 股价大涨26.26%报0.115美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618918518","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618918518?lang=zh_cn&edition=full","pubTime":"2026-03-11 03:43","pubTimestamp":1773171781,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日03时43分，美国OTC市场Lianbio股票出现波动，股价急速上涨26.26%。截至发稿，该股报0.115美元/股，成交量5.8535万股，换手率0.05%，振幅13.63%。美国OTC市场Lianbio股票所在的生物技术行业中，整体涨幅为1.57%。美国OTC市场Lianbio公司简介：LianBio 是一家以科学为导向的生物制药公司，致力于为未满足医疗需求的患者开发和商业化药物，最初专注于大中华区和其他亚洲市场的授权资产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311034301a6b61654&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311034301a6b61654&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","BK4139","LIANY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618990263","title":"Savara, Inc.盘中异动 大幅拉升5.16%报5.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618990263","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618990263?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:51","pubTimestamp":1773150685,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日21时51分，Savara, Inc.股票出现波动，股价快速拉升5.16%。截至发稿，该股报5.71美元/股，成交量9.1595万股，换手率0.05%，振幅4.79%。Savara, Inc.股票所在的生物技术行业中，整体涨幅为1.98%。其相关个股中，Longeveron Inc.、Mink Therapeutics, Inc.、Acurx Pharmaceuticals, Inc.涨幅较大，Biorestorative Therapies, Inc.、Mink Therapeutics, Inc.、Scisparc Ltd.较为活跃，换手率分别为576.95%、233.82%、145.88%，振幅较大的相关个股有Longeveron Inc.、Acurx Pharmaceuticals, Inc.、Artelo Biosciences, Inc.，振幅分别为54.24%、28.12%、20.22%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310215125a6b5a7f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310215125a6b5a7f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVRA","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618672519","title":"Pmv Pharmaceuticals, Inc.盘中异动 快速上涨5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618672519?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:47","pubTimestamp":1773150443,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日21时47分，Pmv Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.52%。截至发稿，该股报1.72美元/股，成交量4.8994万股，换手率0.09%，振幅6.75%。Pmv Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.71%。其相关个股中，Mink Therapeutics, Inc.、Longeveron Inc.、Biorestorative Therapies, Inc.涨幅较大，Biorestorative Therapies, Inc.、Mink Therapeutics, Inc.、Scisparc Ltd.较为活跃，换手率分别为572.75%、230.98%、145.75%，振幅较大的相关个股有Acurx Pharmaceuticals, Inc.、Longeveron Inc.、Artelo Biosciences, Inc.，振幅分别为24.04%、24.02%、20.22%。Pmv Pharmaceuticals, Inc.公司简介：PMV Pharmaceuticals Inc是一家精密肿瘤学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031021472497ac1e0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031021472497ac1e0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN","PMVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117154393","title":"Longeveron公布2B期临床试验结果：干细胞疗法显著改善老年衰弱患者状况，成果发表于《Cell Stem Cell》","url":"https://stock-news.laohu8.com/highlight/detail?id=1117154393","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117154393?lang=zh_cn&edition=full","pubTime":"2026-02-26 00:09","pubTimestamp":1772035741,"startTime":"0","endTime":"0","summary":"Longeveron Inc (LGVN) 宣布，其针对老年衰弱患者的2B期临床试验取得积极成果。研究数据显示，采用干细胞疗法后，患者的整体健康状况获得显著改善。这一重要发现已发表于国际权威期刊《Cell Stem Cell》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122412204","title":"Longeveron Inc：针对左心发育不全综合征的2B期临床试验预计于2026年第三季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1122412204","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122412204?lang=zh_cn&edition=full","pubTime":"2026-02-14 05:32","pubTimestamp":1771018331,"startTime":"0","endTime":"0","summary":"生物制药公司Longeveron Inc近日披露了其研发管线的最新进展。公司宣布，针对罕见先天性心脏病——左心发育不全综合征（HLHS）的2B期临床试验，预计将在2026年第三季度正式启动。这一关键性临床试验的推进，标志着公司在细胞疗法治疗严重心脏病领域迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608785354","title":"Longeveron Inc.盘中异动 大幅上涨5.43%报0.565美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608785354","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608785354?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:38","pubTimestamp":1770129482,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日22时38分，Longeveron Inc.股票出现波动，股价大幅上涨5.43%。截至发稿，该股报0.565美元/股，成交量9371股，换手率0.04%，振幅5.41%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.32%。其相关个股中，Liminatus Pharma Inc C/Wts 30/04/2030 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Liminatus Pharma, Inc.涨幅较大，Cdt Equity Inc.、Pmgc Holdings Inc.、Liminatus Pharma, Inc.较为活跃，换手率分别为614.12%、567.24%、43.34%，振幅较大的相关个股有Liminatus Pharma Inc C/Wts 30/04/2030 、Briacell Therapeutics Corp C/Wts 26/02/2026、阿诺医药，振幅分别为70.33%、32.58%、17.80%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203223802a47803ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203223802a47803ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158183115","title":"Longeveron获FDA批准召开C类会议，关键性二期临床试验（Elpis II）数据揭盲在即，评估左心发育不全综合征疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1158183115","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158183115?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:15","pubTimestamp":1769436920,"startTime":"0","endTime":"0","summary":"生物技术公司Longeveron Inc宣布，美国食品药品监督管理局（FDA）已批准其召开C类会议的请求。此次会议旨在为其针对左心发育不全综合征（HLHS）疗法的关键性二期临床试验（Elpis II）的数据解读进行预备讨论。该试验的数据结果即将公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603653984","title":"Longeveron Inc.盘中异动 早盘股价大跌5.53%报0.540美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603653984","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603653984?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:52","pubTimestamp":1768315940,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日22时52分，Longeveron Inc.股票出现异动，股价急速下挫5.53%。截至发稿，该股报0.540美元/股，成交量3.9336万股，换手率0.18%，振幅2.61%。Longeveron Inc.股票所在的生物技术行业中，整体跌幅为0.15%。Longeveron Inc.公司简介：Longeveron Inc是一家临床阶段的生物技术公司，开发再生医学，以满足特定的与年龄相关和危及生命的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011322522097a1a85a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011322522097a1a85a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115329074","title":"Longeveron首席科学官和首席医学官被选为环球心血管临床试验论坛发言人","url":"https://stock-news.laohu8.com/highlight/detail?id=1115329074","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115329074?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:16","pubTimestamp":1764771402,"startTime":"0","endTime":"0","summary":"Longeveron首席科学官和首席医学官被选为环球心血管临床试验论坛的发言人。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195951704","title":"Longeveron获得加拿大专利：使用干细胞治疗非缺血性扩张型心肌病和与炎症老化相关的衰弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1195951704","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195951704?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:16","pubTimestamp":1764685016,"startTime":"0","endTime":"0","summary":"Longeveron获得加拿大专利，旨在使用干细胞治疗非缺血性扩张型心肌病以及与炎症老化相关的衰弱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128401372","title":"最新数据显示Longeveron新MRI生物标志物将神经炎症与轻度阿尔茨海默病患者的临床结果联系起来，发布于阿尔茨海默病临床试验会议（CTAD 2025）","url":"https://stock-news.laohu8.com/highlight/detail?id=1128401372","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128401372?lang=zh_cn&edition=full","pubTime":"2025-12-02 01:01","pubTimestamp":1764608490,"startTime":"0","endTime":"0","summary":"最新数据显示Longeveron新MRI生物标志物将神经炎症与轻度阿尔茨海默病患者的临床结果联系起来，发布于阿尔茨海默病临床试验会议（CTAD 2025）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518274562","title":"Longeveron Inc.盘中异动 股价大跌5.30%报1.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274562?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:45","pubTimestamp":1741617931,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时45分，Longeveron Inc.股票出现波动，股价快速跳水5.30%。截至发稿，该股报1.43美元/股，成交量4.4991万股，换手率0.30%，振幅4.64%。Longeveron Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3490.20%、767.40%、665.59%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.34%、41.36%、40.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224531964047d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224531964047d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518442576","title":"Longeveron Inc.2024财年实现净利润-15.97百万美元，同比增加25.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518442576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518442576?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449657,"startTime":"0","endTime":"0","summary":"3月9日，Longeveron Inc.公布财报，公告显示公司2024财年净利润为-15.97百万美元，同比增加25.41%；其中营业收入为2.39百万美元，同比增加237.09%，每股基本收益为-2.62美元。从资产负债表来看，Longeveron Inc.总负债3.67百万美元，其中短期债务623000.00美元，资产负债比为6.97，流动比率为7.61。机构评级：截至2025年3月9日，当前有3家机构对Longeveron Inc.目标价做出预测，其中目标均价为8.67美元，其中最低目标价为6.00美元，最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000213abef97de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000213abef97de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517492596","title":"Longeveron Inc.盘中异动 下午盘大幅上涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517492596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517492596?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:38","pubTimestamp":1741203486,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时38分，Longeveron Inc.股票出现异动，股价快速拉升5.26%。截至发稿，该股报1.40美元/股，成交量8.823万股，换手率0.59%，振幅6.02%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为2.02%。Longeveron Inc.公司简介：Longeveron Inc 是一家处于临床阶段的生物技术公司，致力于开发再生药物，以满足与衰老相关和危及生命的特殊疾病方面尚未得到满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306033807abea0714&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306033807abea0714&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516342136","title":"Longeveron Inc.盘中异动 股价大涨8.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516342136","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516342136?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012364,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Longeveron Inc.股票出现波动，股价大幅拉升8.55%。截至发稿，该股报1.65美元/股，成交量108.495万股，换手率7.31%，振幅4.61%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.42%、27.27%、22.55%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Cibus, Inc.，振幅分别为21.22%、19.25%、9.55%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223244a25d401b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223244a25d401b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516334302","title":"Longeveron(LGVN.US)：2024年Q4财报实现营收60.3万美元，前值为6.3万美元，预期值为66万美元；每股收益为-0.27美元，前值为-2.50美元，预期值为-0.36美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516334302","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516334302?lang=zh_cn&edition=full","pubTime":"2025-03-01 05:36","pubTimestamp":1740778585,"startTime":"0","endTime":"0","summary":"Longeveron(LGVN.US)：2024年Q4财报实现营收60.3万美元，前值为6.3万美元，预期值为66万美元；每股收益为-0.27美元，前值为-2.50美元，预期值为-0.36美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01053648470332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195717291","title":"Longeveron 2024财年GAAP每股收益$(2.62)优于预期$(3.53)，销售额$239.2万优于预期$214.3万","url":"https://stock-news.laohu8.com/highlight/detail?id=1195717291","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195717291?lang=zh_cn&edition=full","pubTime":"2025-03-01 05:14","pubTimestamp":1740777251,"startTime":"0","endTime":"0","summary":"Longeveron报告的季度每股亏损为$，优于分析师一致预期的$，超出25.78%。以上内容来自Benzinga Earnings专栏，原文如下：Longeveron  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 25.78 percent. The company reported quarterly sales of $2.392 million which beat the analyst consensus estimate of $2.143 million by 11.63 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Longeveron 2024财年GAAP每股收益$(2.62)优于预期$(3.53)，销售额$239.2万优于预期$214.3万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.0642},{"period":"1month","weight":-0.3207},{"period":"3month","weight":0.2616},{"period":"6month","weight":0.1775},{"period":"1year","weight":-0.4728},{"period":"ytd","weight":0.3962}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0459},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.2503},{"period":"ytd","weight":0.087}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Longeveron Inc于2014年10月9日成立为特拉华州有限责任公司，并于2014年12月15日获授权在佛罗里达州开展业务。该公司是一家临床阶段的生物技术公司，开发再生药物以满足未满足的医疗需求。该公司的主要研究产品是Lomecel-B牌MSCs，这是一种从年轻、健康的成年捐献者的骨髓中分离出来的同种异体药物信号传导细胞（MSC）治疗产品。Lomecel-B具有多种作用模式，包括促血管、促再生和抗炎机制，促进组织修复和愈合，在一系列疾病领域具有广泛的潜在应用前景。该公司目前正在开发三种临床适应症：左心发育不全综合征（HLHS）、衰老相关的虚弱和阿尔茨海默病（AD）。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.146765},{"month":2,"riseRate":0,"avgChangeRate":-0.052773},{"month":3,"riseRate":0.5,"avgChangeRate":0.193379},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.138428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.145847},{"month":6,"riseRate":0.8,"avgChangeRate":0.122312},{"month":7,"riseRate":0.6,"avgChangeRate":0.185232},{"month":8,"riseRate":0,"avgChangeRate":-0.329414},{"month":9,"riseRate":0.2,"avgChangeRate":-0.104571},{"month":10,"riseRate":0.4,"avgChangeRate":-0.0027},{"month":11,"riseRate":0.4,"avgChangeRate":1.29104},{"month":12,"riseRate":0,"avgChangeRate":-0.282059}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Longeveron Inc(LGVN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Longeveron Inc(LGVN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}